-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點摘要如下:GWO公佈的基本利潤為12.39億加元,較去年同期成長20%;基本每股收益為1.37加元,較去年同期成長23%。基本淨資產收益率達19.1%,年增190個基點,首次達到公司19%的中期目標。所有四個營運部門的基本盈利均實現兩位數增長,主要得益於市場升值帶來的手續費收入增加、資本和風險解決方案業務新業務量的持續增長以及保險體驗的改善。美國業務表現強勁,基本獲利達3.14億美元,較去年成長23%;Empower Retirement的淨計畫資金流入達53億美元。公司維持了穩健的資本狀況,LICAT比率為129%,季增100個基點,基本資本產生率超過80%。股東價值回報依然強勁,本季回購了5.67億加元的股份,季度股息成長10%至每股0.67加元。客戶總資產達3.3兆加元,效率比率提升220個基點至54.5%。
Related Articles
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.